Skip to main content

Table 5 Determinants of receiving anticoagulants in the 6 months after the diagnosis of atrial fibrillation (binary logistic regression analysis, n = 1830)

From: Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study

 

Bivariate

P value

Multivariable

P value

 

OR (95 % CI)

OR 95 % CI

Age (years)a

0.98 (0.96–0.99)

<0.001

1.00 (0.98–1.01)

0.74

Men

1.3 (1.1–1.6)

0.002

1.5 (1.2–1.8)

0.001

Medicationa

    

 Digitalis

1.9 (1.4–2.5)

<0.001

2.0 (1.4–2.7)

<0.001

 Antiarrhythmic drug

2.4 (1.9–3.0)

<0.001

2.0 (1.6–2.5)

<0.001

 Antihypertensive medication

    

  Diuretic

2.5 (2.1–3.0)

<0.001

1.5 (1.2–1.9)

0.001

  β blocker

3.1 (2.5–3.7)

<0.001

2.4 (1.9–2.9)

<0.001

  Calcium channel blocker

2.2 (1.7–2.8)

<0.001

1.6 (1.2–2.1)

0.003

  ACE-inhibitor

2.1 (1.7–2.6)

<0.001

1.5 (1.1–1.9)

0.003

  ARB

3.0 (2.2–4.3)

<0.001

2.3 (1.6–3.4)

<0.001

Comorbiditya

    

 CHADS2 scoreb

1.0 (0.94–1.1)

0.64

1.1 (0.99–1.3)c

0.079

 CHA2DS2-VASc scoreb

0.98 (0.92–1.0)

0.57

1.1 (0.99–1.3)d

0.086

 Charlson Comorbidity Indexb

0.91 (0.86–0.96)

<0.001

0.90 (0.83–0.97)c

0.009

  Myocardial infarction

1.0 (0.79–1.4)

0.77

0.84 (0.61–1.2)

0.29

  Heart failure

0.99 (0.74–1.3)

0.92

1.0 (0.72–1.4)

0.92

  Peripheral vascular disease

1.2 (0.86–1.7)

0.30

1.2 (0.80–1.7)

0.41

  Cerebrovascular event

1.1 (0.82–1.4)

0.66

1.2 (0.86–1.6)

0.32

  Dementia

0.19 (0.097–0.38)

<0.001

0.26 (0.12–0.56)

<0.001

  Chronic pulmonary disease

1.9 (1.0–3.4)

0.041

1.9 (0.97–3.7)

0.062

  History of peptic ulcers

0.74 (0.53–1.0)

0.078

0.66 (0.45–0.96)

0.031

  Liver disease

0.94 (0.55–1.6)

0.81

0.94 (0.51–1.7)

0.85

  Diabetes

1.2 (0.96–1.6)

0.11

1.1 (0.85–1.5)

0.40

  Hemiplegia

0.60 (0.28–1.3)

0.18

0.77 (0.33–1.8)

0.56

  Renal disease

0.84 (0.73–0.97)

0.021

0.88 (0.74–1.0)

0.14

  History of tumours

0.70 (0.53–0.93)

0.013

0.67 (0.49–0.92)

0.012

  Leukaemia

0.26 (0.029–2.3)

0.23

0.36 (0.038–3.5)

0.38

  Lymphoma

1.4 (0.31–6.2)

0.66

0.93 (0.19–4.5)

0.92

 Hypertension

1.3 (1.0–1.5)

0.016

1.0 (0.82–1.3)

0.86

 Valve disease

1.2 (0.88–1.6)

0.24

1.2 (0.87–1.8)

0.24

 Cerebrovascular event in the first 6 months after diagnosis of atrial fibrillation

1.6 (1.0–2.6)

0.042

1.8 (1.0–3.1)

0.039

  1. a All variables were recorded at baseline (= date of the diagnosis of atrial fibrillation for the case), except cerebrovascular event in the first 6 months after the diagnosis of atrial fibrillation; b, per point increase; c, adjusted for age, gender, digitalis intake, antiarrhythmic drug intake, diuretic intake, β blocker intake, calcium channel blocker intake, ACE inhibitor intake, ARB intake, valve disease, cerebrovascular event in the first 6 months after diagnosis of atrial fibrillation and CHADS2 or Charlson Comorbidity index; d, adjusted for age, digitalis intake, antiarrhythmic drug intake, diuretic intake, β blocker intake, calcium channel blocker intake, ACE inhibitor intake, ARB intake, valve disease, cerebrovascular event in the first 6 months after diagnosis of atrial fibrillation and Charlson Comorbidity index (the correlation coefficient between the CHADS2 and the CHA2DS2-VASc score was 0.91)
  2. OR odds ratio, CI confidence interval, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us